278 related articles for article (PubMed ID: 30713759)
61. [Mechanisms of Participation of the Urokinase Receptor in Directed Axonal Growth].
Klimovich PS; Semina EV
Mol Biol (Mosk); 2020; 54(1):103-113. PubMed ID: 32163394
[TBL] [Abstract][Full Text] [Related]
62. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor.
Shanmukhappa K; Sabla GE; Degen JL; Bezerra JA
BMC Gastroenterol; 2006 Nov; 6():40. PubMed ID: 17134505
[TBL] [Abstract][Full Text] [Related]
63. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
64. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
65. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
66. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
67. Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics.
Kumar AA; Vine KL; Ranson M
Mol Pharm; 2023 Jun; 20(6):2766-2780. PubMed ID: 37119285
[TBL] [Abstract][Full Text] [Related]
68. Urokinase induces receptor mediated brain tumor cell migration and invasion.
MacDonald TJ; DeClerck YA; Laug WE
J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
[TBL] [Abstract][Full Text] [Related]
69. Urokinase receptor regulates nerve regeneration through its interaction with α5β1-integrin.
Klimovich PS; Semina EV; Karagyaur MN; Rysenkova KD; Sysoeva VY; Mironov NA; Sagaradze GD; Az'muko AA; Popov VS; Rubina KA; Tkachuk VA
Biomed Pharmacother; 2020 May; 125():110008. PubMed ID: 32187956
[TBL] [Abstract][Full Text] [Related]
70. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
Waltz DA; Sailor LZ; Chapman HA
J Clin Invest; 1993 Apr; 91(4):1541-52. PubMed ID: 8386190
[TBL] [Abstract][Full Text] [Related]
71. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
72. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2.
de Paulis A; Montuori N; Prevete N; Fiorentino I; Rossi FW; Visconte V; Rossi G; Marone G; Ragno P
J Immunol; 2004 Nov; 173(9):5739-48. PubMed ID: 15494526
[TBL] [Abstract][Full Text] [Related]
73. Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.
Kocić J; Santibañez JF; Krstić A; Mojsilović S; Ilić V; Bugarski D
Int J Biochem Cell Biol; 2013 Feb; 45(2):464-75. PubMed ID: 23183001
[TBL] [Abstract][Full Text] [Related]
74. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
McGuire PG; Jones TR; Talarico N; Warren E; Das A
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2736-42. PubMed ID: 12766081
[TBL] [Abstract][Full Text] [Related]
75. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
76. Effects of transforming growth factor-β1 on plasminogen activation in stem cells from the apical papilla: role of activating receptor-like kinase 5/Smad2 and mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signalling.
Chang MC; Chang HH; Hsieh WC; Huang WL; Lian YC; Jeng PY; Wang YL; Yeung SY; Jeng JH
Int Endod J; 2020 May; 53(5):647-659. PubMed ID: 31955434
[TBL] [Abstract][Full Text] [Related]
77. Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours.
Anwar Sh; Yanai T; Sakai H
J Comp Pathol; 2015 Nov; 153(4):278-82. PubMed ID: 26286429
[TBL] [Abstract][Full Text] [Related]
78. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
79. Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Rysenkova KD; Klimovich PS; Shmakova AA; Karagyaur MN; Ivanova KA; Aleksandrushkina NA; Tkachuk VA; Rubina KA; Semina EV
Cell Signal; 2020 Nov; 75():109741. PubMed ID: 32822758
[TBL] [Abstract][Full Text] [Related]
80. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
